Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia

NCT05586971 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT05586971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05586971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
Lead sponsor
LG Chem
Phase
Phase 3
Overall status
Completed
Start date
March 30, 2023
Completion date
May 6, 2025
Enrollment
2,202 (actual)
Sites
279

Conditions

As the registry lists them; a condition with its own page is linked.

gout, gout flare, hyperuricemia, tophi